ATE122235T1 - Staupevirus-impfstoff. - Google Patents

Staupevirus-impfstoff.

Info

Publication number: ATE122235T1
Authority: AT; Austria
Prior art keywords: canine distemper; virus; distemper virus; distense; virus vaccine
Prior art date: 1987-03-09

Application number

AT88301296T

Other languages

English (en)

Inventor

Edmund P Bass

William H Kelsey

Michael D Mcfarland

Original Assignee

Miles Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-09

Filing date

1988-02-17

Publication date

1995-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21817338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE122235(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-02-17 Application filed by Miles Inc filed Critical Miles Inc

1995-05-15 Application granted granted Critical

1995-05-15 Publication of ATE122235T1 publication Critical patent/ATE122235T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 3
241000700605 Viruses Species 0.000 title abstract 2
241000712083 Canine morbillivirus Species 0.000 abstract 3
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 abstract 2
230000005855 radiation Effects 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 1
239000000568 immunological adjuvant Substances 0.000 abstract 1
230000002779 inactivation Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/175—Canine distemper virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
- C12N2760/18463—Methods of inactivation or attenuation by chemical treatment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT88301296T 1987-03-09 1988-02-17 Staupevirus-impfstoff. ATE122235T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2381487A	1987-03-09	1987-03-09

Publications (1)

Publication Number	Publication Date
ATE122235T1 true ATE122235T1 (de)	1995-05-15

Family

ID=21817338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT88301296T ATE122235T1 (de)	1987-03-09	1988-02-17	Staupevirus-impfstoff.

Country Status (6)

Country	Link
EP (2)	EP0282179B1 (de)
JP (1)	JPS63277633A (de)
AT (1)	ATE122235T1 (de)
CA (1)	CA1337268C (de)
DE (1)	DE3853736T2 (de)
ZA (1)	ZA881239B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4136900C1 (de) *	1991-11-09	1993-07-29	Schaper & Bruemmer Gmbh & Co Kg, 3320 Salzgitter, De
ZA93216B (en) *	1992-01-17	1993-08-18	Solvay Animal Health Inc	Vaccine containing acemannan as an adjuvant.
EP0679088B1 (de)	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Pulmonale abgabe von aktiven fragmenten des parathormons
ATE416755T1 (de)	1994-03-07	2008-12-15	Nektar Therapeutics	Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1280520E (pt)	2000-05-10	2014-12-16	Novartis Ag	Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1458360E (pt)	2001-12-19	2011-07-13	Novartis Ag	Derivados de indole como agonistas do recetor s1p1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4693981A (en) *	1983-12-20	1987-09-15	Advanced Genetics Research Institute	Preparation of inactivated viral vaccines
US4545987A (en) *	1983-12-20	1985-10-08	Advanced Genetics Research Institute	Psoralen inactivated double-stranded RNA viral vaccines

1988
- 1988-02-16 CA CA000558957A patent/CA1337268C/en not_active Expired - Fee Related
- 1988-02-17 DE DE3853736T patent/DE3853736T2/de not_active Expired - Lifetime
- 1988-02-17 EP EP88301296A patent/EP0282179B1/de not_active Expired - Lifetime
- 1988-02-17 AT AT88301296T patent/ATE122235T1/de not_active IP Right Cessation
- 1988-02-17 EP EP19920109639 patent/EP0506147A3/de not_active Withdrawn
- 1988-02-23 ZA ZA881239A patent/ZA881239B/xx unknown
- 1988-03-09 JP JP63053849A patent/JPS63277633A/ja active Pending

Also Published As

Publication number	Publication date
ZA881239B (en)	1988-08-17
CA1337268C (en)	1995-10-10
DE3853736D1 (de)	1995-06-14
DE3853736T2 (de)	1995-09-28
JPS63277633A (ja)	1988-11-15
EP0282179B1 (de)	1995-05-10
EP0506147A2 (de)	1992-09-30
EP0506147A3 (de)	1992-10-21
AU1176088A (en)	1988-09-08
AU614735B2 (en)	1991-09-12
EP0282179A2 (de)	1988-09-14
EP0282179A3 (en)	1990-01-31

Legal Events

Date	Code	Title	Description
1995-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE122235T1 (de)	1995-05-15	Staupevirus-impfstoff.
FI943171A0 (fi)	1994-07-01	Ureaasipohjainen rokote Helicobacter-infektiota vastaan
MX9301706A (es)	1994-05-31	Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
DE3853210D1 (de)	1995-04-06	Verwendung eines viralen glykoprotein-impstoffes für intranasale immunisierung gegen eine virusinfektion.
NZ192477A (en)	1983-02-15	Method for protecting dogs against virulent canine parvovirus using inactivated virus vaccine
SG73999A1 (en)	2000-07-18	Hepatitis a virus vaccines
MY103575A (en)	1993-08-28	Cannie coronavirus vaccine
DK0848615T3 (da)	2005-10-03	Muilti-undertyoe-FIV-vacciner
ATE19591T1 (de)	1986-05-15	Virus der infektioesen katzen-bauchfellentzuendung, seine herstellung und es enthaltende vakzine.
ES2062364T3 (es)	1994-12-16	Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
HU9202976D0 (en)	1992-11-30	Vaccine acting against anaemy of chicken
ES500199A0 (es)	1982-01-16	Un procedimiento para preparar una vacuna de virus de la ra-bia inactivados
AR016987A1 (es)	2001-08-01	Composiciones acuosas de vacuna acuosaa para la profilaxis de hepatitis b o hepatitis b/a
DZ1550A1 (fr)	2002-02-17	Vaccin depourvu de cellules contre le virus de la maladie marek.
ES2095477T3 (es)	1997-02-16	Metodo para detectar dosis de radiacion utilizando material termoluminiscente.
ES2068883T3 (es)	1995-05-01	Vacunas combinadas vivas.
ATE16348T1 (de)	1985-11-15	Ozon-inaktivierte keime als vakzine.
NO884921L (no)	1990-05-07	Fremgangsmaate for fremstilling av valpesyke-vaksine.
NL300073I1 (nl)	2002-02-01	Vaccin.
ES2055610T3 (es)	1994-08-16	Vacuna contra hrsv.
DK0485463T3 (da)	1995-11-27	Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
RO76563A2 (ro)	1981-04-30	Procedeu de stabilizare a unui vaccin antiherpetic
DK0542895T3 (da)	1997-05-12	Krydsreaktiv influenza A immunisering
Felfe et al.	1985	Trends in production of foot-and-mouth disease vaccine.
SU1565027A1 (ru)	1996-05-20	Инактиватор вируса западного нила